# Probing Glycosaminoglycan–Protein Interactions: Applications of Surface Plasmon Resonance

**Authors:** Changkai Bu, Lin Pan, Lianli Chi, Vitor H. Pomin, Jonathan S. Dordick, Chunyu Wang, Fuming Zhang

PMC · DOI: 10.3390/bios16020071 · Biosensors · 2026-01-25

## TL;DR

This review explores how surface plasmon resonance is used to study interactions between glycosaminoglycans and proteins, highlighting recent advances and challenges in the field.

## Contribution

The paper provides a systematic and up-to-date review of SPR applications in glycosaminoglycan–protein interaction studies.

## Key findings

- SPR offers label-free, real-time insights into GAG–protein binding kinetics and specificity.
- Recent technological advances improve SPR sensitivity and throughput for GAG studies.
- GAG heterogeneity and immobilization remain significant experimental challenges.

## Abstract

Glycosaminoglycans (GAGs) are highly negatively charged polysaccharides that play essential roles in numerous physiological and pathological processes through their interactions with proteins. These interactions govern cellular signaling, inflammation, coagulation, and recognition. Surface Plasmon Resonance (SPR) has emerged as a key biophysical technique for label-free, real-time characterization of biomolecular interactions, offering insights into binding kinetics, affinity, and specificity. SPR-based approaches to glycosaminoglycan–protein interaction studies offer powerful tools for elucidating the roles of GAGs in a wide range of physiological and pathological processes. In this review, we systematically discuss experimental strategies, data analysis methods, and representative applications of SPR-based glycosaminoglycan–protein interactions. Special attention is given to the challenges associated with GAG heterogeneity and immobilization, as well as recent technological advances that enhance sensitivity and throughput. To our knowledge, this review represents one of the first systematic and up-to-date summaries specifically focused on recent advances in applying SPR to the study of glycosaminoglycan–protein interactions.

## Full-text entities

- **Genes:** E (envelope protein) [NCBI Gene 43740570], FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260] {aka BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, SERPINC1 (serpin family C member 1) [NCBI Gene 462] {aka AT3, AT3D, ATIII, ATIII-R2, ATIII-T1, ATIII-T2}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, ITIH4 (inter-alpha-trypsin inhibitor heavy chain 4) [NCBI Gene 3700] {aka GP120, H4P, IHRP, ITI-HC4, ITIHL1, PK-120}, SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, FGF1 (fibroblast growth factor 1) [NCBI Gene 2246] {aka AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-1}, CXCL2 (C-X-C motif chemokine ligand 2) [NCBI Gene 2920] {aka CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, F10 (coagulation factor X) [NCBI Gene 2159] {aka FX, FXA}, SDC2 (syndecan 2) [NCBI Gene 6383] {aka CD362, HSPG, HSPG1, SYND2}, S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, SPR (sepiapterin reductase) [NCBI Gene 6697] {aka SDR38C1}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, CS-E [NCBI Gene 1433], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, FGFR2 (fibroblast growth factor receptor 2) [NCBI Gene 2263] {aka BBDS, BEK, BFR-1, CD332, CEK3, CFD1}
- **Diseases:** infection (MESH:D007239), blood coagulation (MESH:D001778), injury to (MESH:D014947), Inflammation (MESH:D007249), cancer (MESH:D009369)
- **Chemicals:** carboxymethyl dextran (MESH:C014392), GAG (MESH:D006025), KS (MESH:D011188), oligosaccharide (MESH:D009844), 6-O-sulfate (-), DS (MESH:D003903), HS (MESH:D006497), carbohydrate (MESH:D002241), FucCS (MESH:C517150), Amine (MESH:D000588), Thiol (MESH:D013438), CS (MESH:D002586), maleimide (MESH:C043592), divalent cation (MESH:D002413), glucosamine (MESH:D005944), fucose (MESH:D005643), hydrogen (MESH:D006859), heparin (MESH:D006493), hydrazide (MESH:D006834), dermatan sulfate (MESH:D003871), Tween-20 (MESH:D011136), -O- (MESH:D010100), salt (MESH:D012492), chondroitin sulfate (MESH:D002809), keratan sulfate (MESH:D007632), gold (MESH:D006046), NaCl (MESH:D012965), metal (MESH:D008670), glycan (MESH:D011134), fucoidans (MESH:C007789), carbodiimide (MESH:D002234), E (MESH:D004540), glycine-HCl (MESH:D005998), NaOH (MESH:D012972), hyaluronan (MESH:D006820), SDS (MESH:D012967), Biotin (MESH:D001710)
- **Species:** Listeria monocytogenes (species) [taxon 1639], Homo sapiens (human, species) [taxon 9606], Aslia pygmaea (species) [taxon 1902836], Dengue virus (no rank) [taxon 12637], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Thyonella gemmata (species) [taxon 206685], Human immunodeficiency virus 1 (no rank) [taxon 11676], Streptococcus pyogenes (species) [taxon 1314]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938546/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938546/full.md

## References

110 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938546/full.md

---
Source: https://tomesphere.com/paper/PMC12938546